Characterisation and evaluation of antiviral recombinant peptides based on the heptad repeat regions of NDV and IBV fusion glycoproteins  by Wang, Xiao-Jia et al.
Virology 416 (2011) 65–74
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roCharacterisation and evaluation of antiviral recombinant peptides based
on the heptad repeat regions of NDV and IBV fusion glycoproteins
Xiao-Jia Wang ⁎, Chuan-Gen Li, Xiao-Jing Chi, Ming Wang ⁎
Key Laboratory of Zoonosis of Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, No. 2, Yuan Ming Yuan West Road, Haidian District, Beijing 100193,
PR China⁎ Corresponding authors. Fax: +86 10 62733961.
E-mail addresses: wangxj@cau.edu.cn (X.-J. Wang), v
0042-6822/$ – see front matter © 2011 Elsevier Inc. Al
doi:10.1016/j.virol.2011.05.001a b s t r a c ta r t i c l e i n f oArticle history:
Received 2 January 2011
Returned to author for revision 18 April 2011
Accepted 2 May 2011
Available online 23 May 2011
Keywords:
Newcastle disease virus
Infectious bronchitis virus
Heptad repeat
Plaque formation
Chicken embryo assay
Broad-spectrum
Antiviral mixed infectionMixed virus infections can cause livestock losses that are more devastating than those caused by single virus
infections. Newcastle disease virus (NDV) and infectious bronchitis virus (IBV), serious threats to the poultry
industry, can give rise to complex mixed infections that hinder diagnosis and prevention. In this study, we
show that newly designed peptides, which are based on the heptad repeat (HR) region of the fusion
glycoproteins from NDV and IBV, have more potent antiviral activity than the mother HR peptides. Plaque
formation and chicken embryo infectivity assays conﬁrmed these results. The novel peptides completely
inhibited single virus infections and mixed infections caused by NDV and IBV. Furthermore, we assessed cell
toxicity and possible targets for the peptides, thereby strengthening the notion that HR2 is an attractive site
for therapeutic intervention. These results suggest the possibility of designing a relatively broad-spectrum
class of antiviral peptides that can reduce the effects of mixed-infections.etdean@cau.edu.cn (M. Wang).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Newcastle disease virus (NDV) and infectious bronchitis virus (IBV)
cause a complex mixed respiratory disease that is difﬁcult to cure.
Livestock losses due tomixed infections can result in greater losses than
single virus infections (Roussan et al., 2008). The entry of NDV, of the
family Paramyxoviridae, and IBV, of the familyCoronaviridae, ismediated
by the viral fusion glycoproteins gF (Lamb et al., 2006) and gS (Xiao and
Dimitrov, 2004), respectively. gF and gS are Class I viral fusion
glycoproteins, similar to the fusion glycoproteins of viruses of the
orthomyxo-, retro- and baculoviridae families (Colman and Lawrence,
2003; Eckert and Kim, 2001; Long et al., 2008). Class I enveloped viruses
adopt a similar molecular mechanism in which a key step is the
formation of a coiled coil between the trimer of heptad repeat 1 (HR1)
andHR2. Three HR2monomers interact with the correspondingHR1 by
surrounding the HR1 trimer in an anti-parallel manner, forming a six-
helix bundle. This six-helix bundle is known as the virus fusion central
core and is believed to bring the viral and cellular membranes closer
together (Bosch et al., 2003; Liu et al., 2004; Wang et al., 2005).
Human immunodeﬁciency virus (HIV) provides a classic example of
Class I virus entry into the host cell and is inhibited by the HR2 peptide.
HR2 binds the endogenous HR1 region in the pre-fusion conformation,
thereby blocking core formation (Bewley et al., 2002). The HIV-1 fusioninhibitor T20 (enfuvirtide, Fuzeon®), which is derived from the gp41
HR2 region, is the only clinically approved peptide fusion inhibitor
(Eckert and Kim, 2001). Although, this agent is effective against wild-
type strains as well as variants that are resistant to multiple RT- and
protease-inhibitors, T-20-resistant HIV-1 strains have emerged. Thus,
there is anurgentneed todevelopnext-generation fusion inhibitors that
suppress T-20-resistant variants and improve antiviral potency. In
addition to peptides from the HR regions, several modiﬁed peptides
have also been developed, including second and third generation
inhibitors (e.g., T1249, T2635, SC34EK and T-20 s138A) (Eggink et al.,
2009; Nishikawa et al., 2009; Pan et al., 2010).
Recent research has demonstrated that Asp632 (D) of HR2
interacts with Lys574 (K) of HR1 to form a salt bridge, which is
critical for six-helix bundle formation and HIV entry (He et al., 2008).
Furthermore, a strategy in which amino acids at solvent-accessible
sites (b, c, f and g) were replacedwith the residues glutamic acid (E) or
lysine (K) (EK motif) was used to enhance the α-helicity of the HR
peptides by possible intra-helical salt bridges (Liu et al., 2009;
Nishikawa et al., 2008, 2009; Oishi et al., 2009). HR2 minimal proteins
based on the multiple HR motifs, which are rich in EK residues, have
been developed and have dramatically increased antiviral potency
compared to the mother HR2 peptide (Shi et al., 2008). It has been
shown that the antiviral activity of HR2 minimal proteins may be
affected by steric and electrostatic barriers if the molecular weight is
greater than 15 kDa (Hamburger et al., 2005). The salt bridge provides
a strategy to improve helical structures, thereby increasing their
activity against virus variants.
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stable six-helix bundle, which mediates membrane fusion by pulling
the viral and cellular membranes closer together. Only a soluble HR2
peptide from NDV produces a potent and speciﬁc fusion inhibition
activity (Wang et al., 2005). In the work described here, we show that
the six-helix bundle is formed by HR1 and HR2 of IBV gS. Based on
this, a tandem peptide of two HR motifs from NDV HR2 and IBV HR2
were designed to study its antiviral activity during mixed infections.
Furthermore, two novel peptides were designed based on the HR2
structures of NDV and IBV using a recombination and mutation
strategy. This approach may lead to the design of a relatively broad-
spectrum class of antiviral inhibitors.
Results
Design of the NOVEL peptides
The peptides NOVEL-1 and NOVEL-2 were designed after compar-
ing the HR2 sequences of NDV and IBV. The primary structure of each
helix consists of a heptad repeat composed of seven residues
commonly denoted by (a–b–c–d–e–f–g)n. HR sequences have been
divided into two characteristic interactive sites (a, d, e) and solvent
accessible sites (b, c, f, g). For NOVEL-1 and NOVEL-2, a series of
systematic replacements with glutamic acid (E) or lysine (K) were
made at sites b, c, f and g (i.e., all charged residues of the EKmotif were
directed toward the solvent). Theoretically, this replacement would
not change the local electrostatic balance. The most important helix-
forming residues of site a are highly conserved leucine (L) or
isoleucine (I) residues, while the residues of sites d and e integrate
the inherent features of amino acids, such as polarity and hydropho-
bicity, of the corresponding regions of the HR2 from different viruses.
Furthermore, new peptides based on computational analysis (using
the software LearnCoil-VMF and ExPASy-Coils) of the formation of
stable (i.e., interaction probability greater than 90%) coiled-coil
structure with both HR1 and HR2 regions were designed. The design
and structure model of NOVEL peptides is shown in Fig. 1.
The design of the NOVEL peptides is a four-step process. As a ﬁrst
step, computational analysiswas used to study the focusedmotif of HR2
domains of NDV and IBV (Fig. 1A1 and B1). The motif that is
indispensable for the formation of the coiled-coil structure (interaction
probability greater than 90%) was focused, as shown in Fig. 1A2 and B2.
This was followed by a series of systematic replacements with charged
amino acids of pairs EE or KKmade at sites b, c, f and g (Fig. 1A3 and B3).
Computational analysis was used again to further analyse the focused
heptad repeat motifs of the EK mutant HR2 domains (Fig. 1A4 and B4).
Finally, the NOVEL peptides were designed based on focused domains
mentioned in Fig. 1A4, B3 and B4. It was relatively easier for the NOVEL-
2 design, which is constructed directly by the overlap of the focused
domains showed in Fig. 1A4 and B3 (Fig. 1C). For NOVEL-1 (Fig. 1D), a
further recombinant and mutant strategy was considered in which
amino acids of YI and VE were used at sites d and e. The use of tyrosineFig. 1. The design and structure model of NOVEL peptides. A, A1, Amino acid sequences
of NDVHR2 with underlines are a and d,e sites, respectively; A2, The focused motif was
predicted by computational analysis; A3, A series of systematic replacements with EE or
KK were made at b, c, f and g sites for focused motif; A4, The further focused heptad
repeat motifs were predicted for EK mutant focused motif. B, B1, Amino acid sequences
of IBVHR2 with underlines are a and d,e sites, respectively; B2, The focused motif was
predicted by computational analysis; B3, A series of systematic replacements with EE or
KK were made at b, c, f and g sites for focused motif; B4, The further focused heptad
repeat motifs were predicted for EK mutant focused motif. C, Construction graph of
NOVEL-2 (N2) peptide based on focused motifs overlapped from Fig. 1A4 and B3. D,
Construction graph of NOVEL-1 (N1) peptide based on focused motifs overlapped from
Fig. 1A4 and B4, in additional, the amino acids of YI and VEwere used at d,e sites and the
special unit of NASDME was afﬁliated to the N-terminal amino acid. E, Proposed helical
wheel of N1 (top) and N2 (bottom). F, Predicted 3-D structure of N1 (top) and N2
(bottom) using Pymolwin bio-software.(Y), valine (V), I and E integrated the inherent features, such as
hydrophobicity, and improved α-helix formation and stability. In
addition, the special unit of NASDMEwas afﬁliated with the N-terminal
aminoacid of theNOVEL-1 peptide. NASDME,which came from theHR1
region of Marek's disease virus (MDV) gH, has a potentα-helix forming
tendency. There is cross-inhibitionbetweenNDVHR2andMDVgHHR1.
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HR1 (unpublished data).
Puriﬁcation of GST fusion and GST cleaved proteins
The target proteins were ﬁrst expressed as a GST fusion protein in
Escherichia coli using the expression vector pGEX-6p-I. The GST fusion
proteins were bound to a Glutathione-Sepharose 4B column and
eluted with reduced glutathione. The GST fusion proteins were
expressed as soluble proteins with 90% purity (Figs. 2A and 3A). The
puriﬁed GST fusion proteins were then cleaved by a GST-fusion
rhinovirus 3C protease. The concentration of GST-cleaved protein in
puriﬁed samples was analysed using 15% tricine SDS-PAGE. The
cleaved proteins (peptides) with over 90% purity were highly soluble
in PBS at a concentration of about 1 mg/ml. After GST-3C cleavage, the
molecular weight (MW) of the HR1 domain from IBV (denoted
IBVHR1) was approximately 6 kDa, IBVHR2 was approximately 4 kDa,
and IBVHR2-linker-NDVHR2 (I-L-N) was approximately 9 kDa
(Fig. 2B). The MWs of NOVEL-1 and NOVEL-2 (denoted N1 and N2 in
the ﬁgures) were comparable (Fig. 3B). MALDI-TOFmass-spectrometry
(MS) further demonstrated that the MWs of NOVEL-1 and NOVEL-2
were 4106.08 and 3909.61 Da, respectively (Fig. 3D and F).
Structural analysis of I-L-N and I2-helix proteins
To study the interaction between HR1 and HR2, IBVHR1 and
IBVHR2 (I2-helix) were mixed and passed over a Superdex G75
column. HR1 and HR2 formed a heterotrimer structure with a MW of
30 kDa, which is approximately the sum of three HR1 and three HR2
molecules. For protein I-L-N, composed of HR2 genes from two
different viruses through a tandem-connection strategy, gel-ﬁltration
showed monomer formation with a MW of 9 kDa, which was
equivalent to the mixture of IBVHR2 and NDVHR2 (Fig. 2C).Fig. 2. SDS-PAGE results and structural analysis of I-L-N and I2-helix proteins. A, From left to
protein, puriﬁed GST-IBVHR2 protein, and puriﬁed GST-I-L-N protein. B, From left to right,
cleavage, IBVHR1 after GST-3C cleavage. C, Gel-ﬁltration analysis of I-L-N peptides and mixe
with dark-coloured line was showed between the eluted volumes corresponding to 42 and 1
molecular HR1 and HR2, indicating the formation of the heterotrimer structure. Under the
coloured line was eluted about 9 kDa, matchingmonomer I-L-N peptide. D, Circular dichroism
unfolded, and I2-helix peptide shows an obvious α-helix structure, with double minima atCircular dichroism (CD) spectrometry showed that the complex of
I2-helix exhibited a strong tendency toward an α-helical secondary
structure. The IBV HR1 and HR2 regions indicated a stable six-helix
bundle (coiled coil) structure, which shared common features with
Class I enveloped viruses. The CD result of I-L-N showed that the
peptide was unfolded, which is similar to the HR2 monomer structure
of other Class I enveloped viruses (Fig. 2D).
Structural analysis of NOVEL-1 and NOVEL-2 peptides
The gel-ﬁltration result of NOVEL-1 showed the formation of a
homo-trimer structure with a MW of about 13 kDa, which is equal to
the sum of three molecular monomer peptides (4106.08 Da each). For
NOVEL-2, the MW of the peak protein was 4 kDa, indicating that the
peptide remained monomeric in the Tris–HCl buffer (Fig. 3C).
The CD spectrum clearly demonstrated that NOVEL-1 and NOVEL-
2 adopted a standard α-helix structure in a PBS buffer solution, and
the α-helix structure disappeared when the temperature exceeded
60 °C and 45 °C, for NOVEL-1 and NOVEL-2, respectively. The CD
spectra of NOVEL-1 and NOVEL-2 remained practically unaltered in
the presence of 25% 2,2,2-triﬂuoroethanol (TFE), suggesting that there
was no effect of polarity on protein conformation when the peptide is
transferred from water to membrane interfaces (Fig. 3E).
Effect of peptides on plaque formation
To test whether the peptides affected virus infectivity, CEF cells
were infected in the presence and absence of each peptide under
conditions described above. Homologous HR2 from NDV and IBV
showed effective and speciﬁc fusion inhibition activity. Cross-
inhibition of heterologous HR2 between two viruses was not
observed. All of the peptides, including homologous HR2, I-L-N,
NOVEL-1 and NOVEL-2, clearly inhibited plaque formation at
concentrations of 25 μM. The most active peptides were NOVEL-1right, protein molecular weight markers (14, 20, 31, 43, 68 kDa), puriﬁed GST-IBVHR1
markers (3.4, 6, 14, 20 kDa), I-L-N peptide after GST-3C cleavage; IBVHR2 after GST-3C
d proteins of IBVHR1 and IBVHR2 (I2-helix). On the Superdex G75 column a clear peak
4 kDa standards, about 30 kDa. Molecular weights match the approximate sum of three
same experimental conditions, on the Superdex G75 column a clear peak with light-
(CD) spectra analysis of the I-L-N and I2-helix peptides. CD showed the I-L-N peptide is
208 nm and 222 nm.
Fig. 3. SDS-PAGE results and structural analysis of synthetic NOVEL peptides. 3A, From left to right, protein molecular weight markers (20, 31, 43 kDa), puriﬁed GST-N2 protein, and
puriﬁed GST-N1 protein. B, From left to right, N1 after GST-3C cleavage, N2 after GST-3C cleavage, protein molecular weight markers (10, 15, 25, 35 kDa). C, On the Superdex G75
column a clear peak with dark-coloured line was showed about 13 kDa. Molecular weight match the approximate sum of three molecular N1, indicating the formation of the homo-
trimer structure. Under the same experimental conditions, on the Superdex G75 column a clear peak with light-coloured line was eluted about 4 kDa, matching monomer N2
peptide. D and F, The mass spectrometry proﬁles show twomajor peaks, 4106.08 Da and 3909.61 Da, matching the molecular weight of the N1 and N2monomer, respectively. E, CD
spectra analysis of the N1 and N2 peptides. N1 and N2 peptides show a typicalα-helix structure, with double minima at 208 nm and 222 nm, in PBS solution with or without 25% TFE.
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90% at concentrations of 5 μM. Homologous HR2 and I-L-N inhibited
viral infection by about 30–40% at 5 μM (Fig. 4).Effect of peptides on chicken embryo infectivity
IBV interferes with NDV infection between 25 and 65 h post-
infection (Gelb et al., 2007; Hidalgo et al., 1985; Raggi and Pignattelli,
1975). The peptides were evaluated for their activity against mixed
virus infections (50 or 100 PFU NDV and 104 PFU IBV) in a chicken
embryo infectivity assay. The life cycle length for virus co-infections is
longer than that of solo NDV infection at virus titres of either 50 or
100 PFU. The death time of 100 h post-infection can be related to the
threshold in embryo infection assays. Eggs that survive for 100 h
generally also survived up to 140 h.Peptides at concentrations of 0.25 and 1.25 mM in 100 μl of
solution were mixed with one or two viruses and injected into the
allantoic cavity of chicken embryos to evaluate in vivo antiviral
activity. Homologous HR2, from either NDV or IBV, had effective and
speciﬁc inhibition activity. Embryos infected with 50 PFU NDV in the
presence of peptides survived longer than 140 h, compared to the
survival time of 65 h in the absence of peptides. The peptides NDVHR2
and NOVEL-1 were effective at concentrations of 0.25 and 1.25 mM,
and NOVEL-2 was effective at a concentration of 0.25 mM. This trend
was also observed in a mixed-infection assay. In addition, the antiviral
activities of homologous HR2 and I-L-N were similar in plaque
formation assays. However, homologous HR2 presented more
advantages than I-L-N in the embryo assay because I-L-N did not
completely inhibit virus infections at concentration of 1.25 mM in
either single or mixed virus infections. In the presence of peptides, the
embryonic eggs survived up to 140 h with negligible virus titre in the
Fig. 4. Effect of peptides at various concentrations on plaque formation. CEF cells were
exposed to active peptides at concentrations of 25 and 5 and 1 and 0.2 μM and virus in
the co- treatment mode. All proteins potentially inhibited plaque formation at protein
concentrations of 25 μM. The most active peptides were N1 and N2 at concentrations of
5 μM, which showed approximately 80–90% plaque inhibition for NDV and IBV. The
results shown are representative of results of three independent experiments. A, CEF
cells were exposed to NDV and the peptides at different concentrations, including
homologous HR2 (i.e., NDVHR2) and N1, N2, I-L-N, and heterologous HR2 (i.e., IBVHR2)
peptides, left to right. B, CEF cells were exposed to IBV and the peptides at different
concentrations, including homologous HR2 (i.e., IBVHR2) and N1, N2, I-L-N, and
heterologous HR2 (i.e., NDVHR2) peptides, left to right.
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infection by speciﬁcally targeting virus particles, rather than inter-
fering with the cellular membrane or by non-speciﬁc binding to
undeﬁned cellular proteins.
At 1.25 mM, NOVEL-2 did not prevent infection following the
introduction of 50 PFU NDV alone or a mixed-infection, although it
showed potent antiviral activity during IBV infection. We concluded
that 0.25 mM of NOVEL-1 is more suitable for use against both NDV
and mixed virus infections, whereas 1.25 mM of NOVEL-2 is more
suitable for use against IBV. Under the same experimental conditions,
all of the peptides signiﬁcantly decreased the effect of 104 PFU IBV on
embryo dwarﬁsm. NOVEL-2 and IBVHR2 were stronger inhibitors
than other peptides at 1.25 mM. No pathology was observed during
IBV infection in the presence of the two peptides at 1.25 mM.
Heterologous HR2 did not provide cross-inhibition between the
two viruses. Notably, NDVHR2 and NOVEL peptides increased survival
for longer than 140 h for embryos infected with either NDV infection
alone or a mixed-infection with 50 PFU NDV. For mixed-infections,
0.25 and 1.25 mM doses of NDVHR2 prevented the haemorrhageinduced by NDV. Meanwhile, 1.25 mM of NDVHR2 only partially
blocked the dwarﬁsm induced by IBV, whereas NOVEL peptides
completely prevented haemorrhage and dwarﬁsm. To further address
the differences in antiviral ability between HR2 and NOVEL peptides,
the inoculum was increased to 100 PFU NDV. Under this condition,
0.25 mM of NOVEL-1 and NOVEL-2 inhibited both NDV and mixed
infections more strongly than HR2. Both NOVEL peptides prolonged
the survival of infected eggs (greater than 140 h) without pathology.
Eggs infected in the presence of 0.25 mM speciﬁc HR2 or I-L-N did not
survive past 55 h, although pathological changes, such as haemor-
rhage, were not obvious. The results from in vivo experiments showed
that NOVEL-1 and NOVEL-2 possess more potent antiviral activity
than HR2 peptides (Fig. 5).
Cytotoxic analysis
To conﬁrm that these peptides did not exert toxic effects on CEF
cells, monolayers were exposed to a range of concentrations (0.2, 1, 5,
25, 50, 250 μM, and 1.25 and 2.5 mM) of each peptide for 24 h, and cell
viability of the cells was assessed by the LDH assay. There was no
signiﬁcant difference between the viability of control (untreated) cells
and cells exposed to the peptides at concentrations below 1.25 mM.
Only NOVEL-1 and NOVEL-2 exhibited cytotoxic effects, which were
observed at concentrations of 2.5 mM. However, peptides at a 2.5 mM
dosage have obvious toxic effects in NDV-infected embryos that
prevent their use.
Interaction of NOVEL-1 and NOVEL-2 with the HR2 region
GST-fused HR2 proteins (including IBNHR2 and NDVHR2) and Flag
fusion NOVEL peptides were constructed. GST-pull down and
immunoprecipitation analyses clearly show the interaction between
HR2 and both NOVEL peptides (Fig. 6). There was no evidence
suggesting possible binding between HR1 and NOVEL peptides under
the current assay conditions (data not shown). CD analysis showed
that equimolar mixtures of HR2 and NOVEL peptides have more
obvious α-helical structures than single peptides. Nevertheless,
mixing HR1 and NOVEL peptides (NOVEL-1 and NOVEL-2) at
equimolar concentrations did not lead to the formation of an α-
helix coiled coil (Fig. 7). Furthermore, the CD spectrum clearly
demonstrated that the thermal denaturation temperature (Tm) of the
HR2–NOVEL (including NOVEL-1 and NOVEL-2) complex (N100 °C)
was higher than that of the homologous HR1–HR2 six-helix bundle
complex (about 85–90 °C), suggesting that the HR2–NOVEL com-
plexes are more stable than the HR1–HR2 complex.
Discussion
The salt bridge between the HR1 and HR2 regions is critical for
Class I virus entry, and electrostatic interaction introduced by EK
substitutions enhances the conformational stability of the six-helix
bundle (He et al., 2008). Structural analysis demonstrated that the
interaction between HIV HR1 and the substitution peptide retains the
ability to form the six-helix bundle structure, despite the substitution
of about one-third of the residues (Nishikawa et al., 2009). Buried salt
bridges have been used successfully in the design of highly speciﬁc
interacting coiled-coil dimers (He et al., 2008; Liu et al., 2009; Vagt et
al., 2009). The innovation of the present study was the design of the
new peptides NOVEL-1 and NOVEL-2. The strategy consisted of
systematic replacements with EE or KK at b, c, f and g sites to form salt
bridges, residue integration of inherent features at a, d and e sites, and
modiﬁcation by the NASDME unit, which showed a potent α-helix
forming tendency laid at the N-termini of NOVEL-1 peptide.
All of the peptides showed potent antiviral activity in the plaque
formation experiment. The most active peptides were NOVEL-1 and
NOVEL-2, which inhibited NDV and IBV infections by approximately
Fig. 5. Effect of the peptides on chicken embryo infectivity. Pathological reduction ﬁgures by co-treatment of virus with or without the peptides in chicken embryos. Antiviral
efﬁciency, including death time of infected embryo and pathology, coincidence rate and corresponding dosage of peptides. Note: severity of pathology is from mild degree (+) to
severe degree (+++). Conspicuous marks with bold font are predominant antiviral peptide. Note: haemorrhage (hemo) is the typical symptoms for NDV infection, and embryo
dwarﬁsm (dwar) is the typical symptoms for IBV infection. The coincidence rate is the proportion of egg number with the identical symptoms of total egg number (3 times and 5 eggs
every time, total up to 15 eggs). * The allantoic ﬂuid of embryonic eggs with negligible virus titre.
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homologous HR2 were similar, and the 50% inhibition concentration
(IC50) was greater than 5 μM (Fig. 4). The embryo infectivity assays
showed that all of the peptides had in vivo antiviral activity. At 0.25
and 1.25 mM, NOVEL-1 showed striking antiviral activity, prolonging
embryo life for more than 140 h in the presence of 50 PFU NDV, and
up to 140 h in the presence of 100 PFU NDV. NOVEL-2, at a
concentration of 1.25 mM, showed the strongest anti-IBV inhibition.
Notably, pathology by 50 PFU/100 PFU NDV and 104 PFU IBV infection
was completely inhibited by the co-treatment of NOVEL peptides
(including NOVEL-1 and NOVEL-2) at concentrations of 0.25 mM,
although mild haemorrhage was observed following infection with
50 PFU and treatment with NOVEL-1 (Fig. 5).
The HRdomain andHRderived peptides inhibitmembrane fusion in
vitro (Colman and Lawrence, 2003; Eckert and Kim, 2001), but few
papers discuss their in vivo inhibition ability. In the present study, we
showed that NOVEL-1 and NOVEL-2 have potent antiviral activity and
provide complete protection at concentrations of 0.25 or 1.25 mM.
However, despite their strong antiviral activity, HR2 from HIV gp41
were ineffective in vivo due to their short half-lives (Kilby et al., 2002).
Recently, cholesterol and PEGmodiﬁcation strategies have been used to
increase the antiviral potency and dramatically extend the peptide half-
lives in vivo (Eggink et al., 2009; Ingallinella et al., 2009; Porotto et al.,
2010). Complete protection was observed when an HR2 peptide that
was treated with cholesterol-PEG was injected into mice at a
concentration of 2–3.5 mg/kg (Ingallinella et al., 2009; Porotto et al.,
2010). Such techniques could be applied to NOVEL-1 and NOVEL-2-
based research to develop longer-acting and relatively broad-spectrum
agents, which are effective against single and mixed virus infections.The CD spectrum clearly demonstrated that both of the newly
designed peptides adopt a standard α-helical structure in polar and
non-polar environments (Fig. 3E) that is different than the unfolded
structure of monomeric HR2 (Wang et al., 2005). Furthermore, the α-
helical structure disappeared when the temperature exceeded 60 °C
and 45 °C for NOVEL-1 and NOVEL-2, respectively, suggesting that the
stability of NOVEL-1 is higher than that of NOVEL-2. The gel-ﬁltration
results indicated that in polar environments NOVEL-1 formed
homotetramers and NOVEL-2 remained a monomer (Fig. 3C). In
addition, hydropathy plots, generated by the software Kyte-Doolittle,
indicated that NOVEL-1 is less hydrophilic than NOVEL-2 (data not
shown). In the embryo infection assay, NOVEL-1 (at 1.25 mM) and
NOVEL-2 (at 0.25 mM) completely eliminated the pathological
changes induced by either NDV infection or IBV and NDV co-infection.
NOVEL-2 (at 1.25 mM) completely eliminated the pathological
changes induced by IBV infection. There is a higher amino acid
identity between NOVEL-2 and IBVHR2 than between NOVEL-1 and
IBVHR2, which may be the reason that NOVEL-2 is more suitable for
use against IBV.
When designing hydrophilic NOVEL-1 and NOVEL-2, no extra
hydrophobic or charged amino acids were introduced. Compared to
the mother peptide HR2 (which does not inhibit virus entry by
affecting the cell membrane), the local electrostatic balance was not
affected by the EK substitutes. It seems that the antiviral function of
NOVEL peptides is not analogous to that of antibiotic peptides that are
rich in positively charged residues and target bacteria by disrupting
membranes. We used an in vitro protein binding assay to directly
verify that NOVEL-1 and NOVEL-2 interact with the HR2 region
(Figs. 6 and 7). HR2 and minimal peptides commonly take HR1 as the
Fig. 6. GST-pull down and immunoprecipitation results. A, Flag fusion peptide (i.e. N1-
Flag or N2-Flag) was incubated with GST fusion HR2 protein (i.e. GST-NDVHR2 or GST-
IBVHR2) or GST protein, mixture proteins were then collected with Sepharose beads,
immunoblots were reacted with Flag antibody. From left to right, GST as bait protein
mixed with CEF cell lysates; GST as bait protein mixed with N2-Flag transfected cell
lysates; GST-NDVHR2 as bait protein mixed with N2-Flag; GST-IBVHR2 as bait protein
mixed with N2-Flag; GST-NDVHR2 as bait protein mixed with N1-Flag transfected cell
lysates; GST-IBVHR2 as bait proteinmixedwith N1-Flag; GST as bait proteinmixedwith
N1-Flag; GST as bait protein mixed with CEF cell lysates. B, Flag fusion peptide (i.e. N1-
Flag or N2-Flag) was incubated with GST fusion HR2 protein (i.e. GST-NDVHR2 or GST-
IBVHR2) or GST, mixture proteins were then collected with protein A and Flag antibody,
immunoblots were reacted with GST antibody. From left to right, N2-Flag transfected
cell lysates with GST; N2-Flag transfected cell lysates mixed with GST-NDVHR2; N2-
Flag transfected cell lysates mixed with GST-IBVHR2; N1-Flag transfected cell lysates
with GST; N1-Flag transfected cell lysates mixed with GST-NDVHR2; N1-Flag
transfected cell lysates mixed with GST-IBVHR2.
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generally poor inhibitors of virus entry because they tend to aggregate
and do not form a coiled-coil trimer (Eckert and Kim, 2001). HR1 has
two distinct modes of inhibitory action: binding the endogenous HR2
region in the pre-fusion conformation (thereby blocking six-helix
bundle formation) and binding the endogenous HR1 region to disrupt
the formation of the internal HR1 trimer (Bewley et al., 2002; Liu et al.,
2007). Recently, the modiﬁed, soluble HR1 exhibited potent antiviral
activity, showing that it can interact with the corresponding HR2 to
form the coiled-coil trimer (Chen et al., 2010). HR1-derived peptides
with the appropriate modiﬁcations are also promising (Izumi et al.,
2010). NOVEL-1 and NOVEL-2 showed an interaction probability of
90–100% for both HR1 and HR2 of the two viruses, according to GOR/
Coils software. Indeed, a few candidate peptides were designed based
on software predictions, including NOVEL-3 (NASDMEIKKYIKKIEE-
VEKKLEEYDKKLEEVN). NOVEL-3 has an interaction probability of 80%
for HR2, but its antiviral activity was 10-fold lower than that ofNOVEL-1 in the plaque formation assay (data not shown). The CD
results showed that the thermal denaturation temperature (Tm) of
HR2 and NOVEL peptide complexes (both NOVEL-1 and NOVEL-2)
was higher than that of the homologous HR1–HR2 six-helix bundle
complex, suggesting that the EK substitution reinforced the afﬁnity of
binding to HR2 through enhanced α-helicity. These results support
the possibility that NOVEL-1 and NOVEL-2 block six-helix bundle
formation, thereby inhibiting virus infection by competition for the
endogenous HR2 region.
It has been proposed that enhanced binding afﬁnity following the
EK substitution confers nonspeciﬁc binding to α-helical regions of
other cellular proteins, such as human serum albumin, which contains
31 α-helical regions (Matsuo et al., 2004). However, further research
veriﬁed that the substitutions were minimally inﬂuenced by the
serum component in plaque formation assays (Nishikawa et al.,
2009). Our study veriﬁed that NOVEL-1 and NOVEL-2 inhibit virus
infection by competitive combination with the endogenous HR2
region of NDV and IBV fusion glycoproteins. Given that HR and HR
minimal proteins are rich in α-helical structures, we cannot exclude
the possibility that the NOVEL peptides interact with α-helical
domains in viral glycoproteins.
The fact that embryos survived infection with two viruses in the
presence of both NOVEL peptide and homologous HR2 at 0.25 mM
beyond 140 h proved that the interaction between NOVEL and HR2
does not affect their antiviral activity conditions (data not shown).
This disagrees with our original hypothesis, which stated that NOVEL
peptides and HR2 interact with each other in vitro, thereby
neutralising their antiviral ability. CD spectrometry showed that the
NOVEL–HR1–HR2 protein mixtures form α-helical secondary struc-
tures (Fig. 7). It is reasonable to infer that the NOVEL peptides and
HR2 interact to form a complex, which binds the endogenous HR1
region and blocks internal HR1 trimer or six-helix bundle formation to
prevent viral infection. It is likely that during the formation of the six-
helix bundle and the fusion process, the fusion glycoprotein changes
its conformation drastically, suggesting that a ﬂexible combination of
the peptides may be required to preserve the actual process.
The interaction probability between NOVEL peptides and HR2
from seven different strains of NDV virus was studied. There are 3–6
amino acid differences between the HR2 domains of the standard
strain (F48E9) and mutant viruses. Coils software predicted a 90–
100% interaction probability which suggests that the NOVEL peptides
can inhibit mutant virus infection. Further studies are needed to
determine if the peptides are effective against other serotypes of NDV
and IBV. In addition, it will be interesting to determine the stage of
virus entry where the NOVEL peptides play a vital role. Considering
the similarity of Class I virus entry models, further work should be
focused on viruses within the Paramyxoviridae, Coronaviridae and
Retroviridae families, which have common HR regions with similar
structures and functions.
Conclusions
1) HR1 and HR2 regions from IBV glycoprotein S form a stable six-
helix bundle (coiled-coil) structure, which shares common
features with Class I enveloped viruses.
2) Both the newly designed NOVEL-1 and NOVEL-2 peptides adopt a
standard α-helix structure in polar and non-polar environments.
Results from vitro and vivo experiments show a more potent
antiviral activity than mother HR2 peptides.
3) NOVEL-1 and NOVEL-2 at concentrations of 0.25 mM in 100 μl of
solution can completely inhibit mixed infection of NDV (100 PFU)
and IBV (104 PFU).
4) NOVEL-1 and NOVEL-2 can inhibit virus infection by competitive
combination with the endogenous HR2 region of NDV and IBV
fusion glycoproteins.
Fig. 7. Circular dichroism results of single or mixed peptides at the equimolar concentration CD spectra was performed to study on secondary structure change of the single peptides
and any combination of two or three peptides (peptides mixture) at the equimolar concentration in PBS with 25% TFE. A, CD results of N2 and IBV gS-derived HR single peptide (i.e.
HR1 or HR2), andmixed proteins including N2 and/or HR peptide. B, CD results of N1 and IBV gS-derived HR single peptide, andmixed proteins including N1 and/or HR peptide. C, CD
results of N2 and NDV gF-derived HR single peptide, and mixed proteins including N2 and/or HR peptide. D, CD results of N1 and NDV gF-derived HR single peptide, and mixed
proteins including N1 and/or HR peptide.
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Prediction and construction of HR2 and HR2 minimal proteins
HR domains of the fusion glycoprotein (gF) from the NDV strain
F48E9 (GenBank Accession No. AAS00690) and the spike glycoprotein
(gS) from the IBV strain H52 (GenBank Accession No. AAK27168)
were used. The software packages LearnCoil-VMF (http://nightingale.
lcs.mit.edu) and ExPASy-Coils (http://www.ch.embnet.org/software/
COILS), which have been used successfully for a number of viral fusion
glycoproteins, were used to study coiled coils. In addition, an
optimised Lupas algorithm was used with window widths of 14, 21
and 28 and the MTIDK matrix. For HR1 and HR2 gene constructions,
the HR1 regions of NDV and IBVwere derived from amino acids 147 to
189 (NDVHR1) and 789 to 840 (IBVHR1), respectively. The HR2
regions of NDV and IBV were derived from amino acids 467 to 501
(NDVHR2) and 1056 to 1089 (IBVHR2), respectively. The predicted
probability of forming coiled coils was nearly 1.0. In addition, IBVHR2-
linker-NDVHR2 (denoted I-L-N; linker sequence is SGGRGG) using a
tandem-gene connection strategy was constructed. The NOVEL-1 and
NOVEL-2 peptideswere designed after comparing theHR2 sequences of
the two viruses, and a series of systematic replacements have been
made. Furthermore, newpeptides based on LearnCoil-VMF and ExPASy-
Coils software predictions of the formation of a stable coiled-coil
structure with both HR1 and HR2 regions were designed. The relevant
substitutions and their helical structures are shown in Fig. 1.
Primer design and gene construction
Genes were constructed using the bridging-PCRmethod and cloned
into the GST fusion expression vector pGEX-6P-I BamHI-XhoI restriction
sites,which includes a rhinovirus 3Cprotease cleavage site for the fusion
protein (the commercial PreScissionTM protease cleavage site). The
positive plasmids were veriﬁed by direct DNA sequencing.Puriﬁcation of GST fusion and GST cleaved proteins
E. coli strain Ros, which was transformed with the recombinant
pGEX-6p-I plasmid, was grown at 37 °C in 2× YTA to an optical density
of 0.8–1.0 (OD at 590 nm) before being induced with 1 mM IPTG for
4 h. Bacterial cells were harvested and lysed by sonication in
phosphate-buffered saline (PBS, pH 7.3). Triton X-100 was added to
a ﬁnal concentration of 1%, and the lysate was incubated for 30 min at
0 °C. The clariﬁed supernatants were passed over to Glutathione-
Sepharose 4B column (GE Healthcare). The GST fusion protein-bound
column was washed with PBS over 10 column volumes and eluted
with reduced glutathione for 3 column volumes. GST fusion proteins
were analysed using 10% SDS-PAGE.
The GST fusion proteinswere cleaved by GST-fusion rhinovirus 3C
protease at 5 °C for 16 h in cleavage buffer (50 mM Tris–HCl pH 7.0,
150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol). PreScission Prote-
ase is a fusion protein of GST and human rhinovirus 3C protease. The
protease speciﬁcally recognises the amino acid sequence Leu-Glu-
Val-Leu-Phe-Gln-Gly-Pro and cleaves between the Gln and Gly
residues. Because the protease is fused to GST, spare GST fusion
proteins and protease, and cleaved GST are easily removed from
cleavage reactions using Glutathione Sepharose (i.e., Glutathione-
Sepharose 4B column). The unbound protein (i.e., GST cleaved
proteins) was extracted and was further separated from GST by
Ultra-15 ultraﬁltration of 30 kDa membranes (Millipore). The GST
cleaved proteins had MW smaller than 10 kDa, which enabled
them to be ﬁltered and collected in the centrifuge tube, while GST
or GST fusion proteins with MW larger than 30 kDa were kept in the
ﬁlter unit. The collected protein was dialysed against PBS and con-
centrated by ultraﬁltration using 3 kDa membranes (Millipore). The
concentration of GST cleaved protein in puriﬁed samples can be
analysed using 15% tricine SDS-PAGE and by standard chromogenic
methods, such as BCA. GST cleaved proteins with over 90% purity
were used for further studies.
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The highly puriﬁed I-L-N, NOVEL-1, NOVEL-2, mixed IBVHR1 and
IBVHR2 proteins (denoted I2-helix) were loaded onto the Superdex
G75 column in a solution buffer of 20 mM Tris–HCl, pH 8.0. The peak
MW was estimated by comparing the substrate with the protein
standards running on the same column. The analytical column was
calibrated with a series of individual runs of standard molecular mass
proteins as markers, including bovine serum albumin (68 kDa), egg
white albumin (43 kDa), ribose nucleotidase (13.7 kDa), aprotinin
(6.5 kDa), antimicrobial peptides (5 kDa), and vitamin B12 (1.4 kDa).
Circular dichroism (CD) spectra analysis
I-L-N and I2-helix, puriﬁed by the gel-ﬁltration method, were
dissolved in PBS (pH 7.4) at a concentration of 30 μM. The
wavelength-dependence of molar ellipticity [θ] was monitored at
25 °C as the average of eight scans in a spectropolarimeter (Model J-
710, JASCO), equipped with a thermoelectric temperature controller.
The NOVEL peptides were incubated at a ﬁnal concentration of 30 μM
in PBS, with or without 25% 2,2,2-triﬂuoroethanol (TFE). TFE is widely
used in conformational studies because it promotes intramolecular
hydrogen bonds in spite of intermolecular interactions with water
molecules. Moreover, as TFE lowers the polarity of the solution, the
environmental changes experienced by the peptides resemble those
of the native sequences during the membrane fusion process
(Akkarawongsa et al., 2009).
CD spectra analysis was performed to study the secondary
structural changes in the single peptides and any combination of
two or three peptides (peptides mixture) at an equimolar concentra-
tion in PBS with 25% TFE. For these studies, a single peptide was
prepared at a concentration of 30 μM, and peptide mixtures were
prepared at an equimolar concentration in a constant volume (for
example, for two peptide mixtures, the ﬁnal concentration of each
peptide is 15 μM).
The thermal denaturation temperature (Tm) was measured at
222 nm by recording the CD signal in the temperature range of 20–
100 °C with a scan rate of 1 °C/min.
Mass spectroscopy (MS) analysis
NOVEL peptides were resolved in 20 mM Tris–HCl (pH 8.0) and
analysed using the Bruker Daltonics Biﬂex III MALDI-TOF Mass
Spectrometer to obtain the molecular weight of the peptides.
Viral stock preparation
Primary chicken embryo ﬁbroblast (CEFs) cells were grown in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
10% foetal calf serum (FCS) and were allowed to attach overnight.
Viruses (NDV strain F48E9 and IBV strain H52) were incubated for 2 h
at 37 °C. Following incubation, the virus samples on the cells were
replaced with DMEM supplemented with 2% FCS, and the cultures
were incubated for another 36 h (for NDV) or 48 h (for IBV) at 37 °C.
Consistent and uniform plaques were observed and counted under an
Olympus microscope, and images were captured using DP Controller
software. NDV from the same passage with 6×107 PFU/ml and IBV
from the same passage with 107 PFU/ml were used in both the plaque
formation and chick egg assays.
Effect of peptides on plaque formation
Peptides were dissolved in DMEM without serum. To assess the
effect of peptides on the inhibition of serially passaged NDV and IBV
infectivity, the cells were incubated with increasing concentrations of
the peptides (0.2, 1, 5, 25 μM) in the presence of the viral inoculum(0.01 PFU/cell for NDV, 5 PFU/cell for IBV) at 37 °C. Two hours later, the
virus–peptide mixtures were replaced with DMEM supplemented with
2%FCS, and the cultureswere incubated for an additional36 (NDV)or 48
(IBV) hrs at 37 °C. Following this incubation, plaque numbers were
counted and thepercentage of plaque inhibition (i.e., the reduction rate)
was normalised to the virus infection using the same inoculumwithout
peptide, whichwas set at 0%. Experiments were performed in triplicate.
Virus yield reduction assay in chicken embryo
Virus was mixed with peptides prior to injection into the allantoic
cavity of 9-day-old SPF chickeneggs and incubatedat 37 °C for 40–140 h
with observation every 5 h. The dead embryoswere stored immediately
at 4 °C, and all embryos were analysed at the same time. Photographs
were taken 140 h post-infection. Experiments were performed in
triplicate using 5 eggs per condition. Injection of virus alone (no
peptide) was included as a control. The virus titre of allantoic ﬂuid was
measured when the embryo was still alive, at 140 h post-infection.
LDH assay for toxicity analysis
Peptide cytotoxicity was measured by a lactate dehydrogenase
(LDH) assay according to the manufacturer's instructions using a
cytotoxicity detection kit (Roche).
GST-pull down and Western blot analysis
A eukaryotic expression plasmid pcDNA3.1(+) containing the
NOVEL gene with a Flag tag was constructed and transfected into CEF
cells using the reagent Lipofectamine™ 2000. Flag-tag puriﬁcation kits
(M&C Company) were used to purify the Flag fusion proteins. Cell
lysate, which contained the Flag fusion NOVEL peptide, was incubated
with puriﬁed GST fusion HR protein (i.e., HR1 and HR2) or GST protein
in the presence of Glutathione-Sepharose 4B beads at 4 °C for at least
8 h. The beads were washed with PBS 5 times, and the proteins were
eluted using 20 mM reduced glutathione. The proteins were analysed
using 15% tricine SDS-PAGE, then transferred onto a nitrocellulose
membrane. The membrane was probed ﬁrst with Flag antibody and
subsequently with an HRP-conjugated goat anti-mouse IgG. The
experiment was performed in triplicate.
Immunoprecipitation and western blot analysis
NOVEL-Flag transfected cell monolayers werewashed 3 timeswith
PBS and suspended in IP buffer (Applygen Technologies, Inc.) in the
presence of a protease inhibitor cocktail (Sigma). The cells were
shaken on ice extensively for 5 min, then centrifuged at 12,000 ×g or
1 min at 4 °C. The supernatant was then transferred to fresh tubes.
Approximately 1 mg of GST fusion HR1 or HR2 protein was added to
the cell supernatant with protein A and Flag antibody followed by
incubation on ice for at least 8 h. The supernatant was removed after
centrifugation at 2000 ×g for 3 min, and the protein A was washed 5
times with PBS. Protein A beads and proteins were analysed using 12%
SDS-PAGE. The proteins were transferred onto a nitrocellulose
membrane, and the membrane was probed with GST antibody and
subsequently with an HRP-conjugated goat anti-mouse IgG. The
experiment was performed in triplicate.
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